Navigation Links
Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
Date:4/24/2013

d the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the ability of AcelRx Pharmaceuticals to successfully complete the clinical trials for the sufentanil NanoTab System; that subsequent analyses of data by regulatory agencies may be subject to differing interpretations;  the success, cost and timing of all product development; the uncertain clinical development process, including the risk that clinical trials have an effective design or deliver data on schedule; AcelRx Pharmaceutical's ability to attract funding partners or collaborators with development, regulatory and commercialization expertise; its ability to obtain sufficient financing to complete registration of its product candidates in the United States and Europe; its ability to obtain and maintain regulatory approvals of its product candidates in the United States and Europe; the market potential for its product candidates; the accuracy of AcelRx Pharmaceuticals' estimates regarding expenses, capital requirements and needs for financing; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings and reports, including its Annual Report on Form 10-K filed with the SEC on March 12, 2013.  AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

(Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
2. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
3. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
4. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
5. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
6. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
7. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
8. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
9. Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
10. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Adaptive Biotechnologies, ... Sequencing (NGS) to profile the adaptive immune system, is ... as Chief Commercial Officer (CCO). The addition of ... recent key hires from leading global healthcare companies, including ... (General Counsel) from Genomic Health and Sean ...
(Date:9/16/2014)... Sept. 16, 2014 EHE International, the recognized leader ... physician network, today announced that David Abrams M.D . ... an EHE-certified preventive care center. Through David Abrams M.D ... region now have greater access to EHE,s preventive care programs ... is proud to add Dr. Abrams M.D. to its growing ...
(Date:9/16/2014)... , Sept. 16, 2014 QPID Health , ... to new headquarters in Boston and ... headquarters will be at 175 Franklin Street in ... marketing teams. QPID Health,s new Southern California ... Carlsbad.  The expansion will help meet the demands of customers ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3EHE International Certifies David Abrams M.D. as Its Newest Partner 2QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2
... 3, 2010 Cardiogenesis Corporation (OTCQB: CGCP), a leading ... diffuse coronary artery disease, today reported financial results for ... 30, 2010. Revenue for the third quarter ... year third quarter revenue of $2,134,000.  Gross margin was ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), ... that it has expanded its Medisystems® in-center product portfolio ... to the terms of the strategic Agreement with Vasc-Alert ... in the United States.   Vasc-Alert, a ...
Cached Medicine Technology:Cardiogenesis Reports Third Quarter 2010 Results 2Cardiogenesis Reports Third Quarter 2010 Results 3Cardiogenesis Reports Third Quarter 2010 Results 4Cardiogenesis Reports Third Quarter 2010 Results 5Cardiogenesis Reports Third Quarter 2010 Results 6NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™ 2NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™ 3
(Date:9/16/2014)... Las Vegas, NV (PRWEB) September 17, 2014 ... Lewis that shows dog owners the true poisonous ingredients in ... homemade dog food recipes has caught the attention of Shane ... their dogs are just as much of a family member ... tragic when their dog dies earlier than it should due ...
(Date:9/16/2014)... the UK report a poorer experience of care during ... on their care, suggests a new study published today ... Obstetrics and Gynaecology ( BJOG ). , Differences ... demonstrated in many areas and have provided the focus ... observed inequalities. , The Oxford University study, funded by ...
(Date:9/16/2014)... Keep that sexy decolletage as you age, and frame ... Face Whisperer Neck & Decollete Cream is made ... Sublime Beauty®. "It contains rich ingredients to care for the ... A special ingredient is Argireline, known as the natural botox, ... comes in an airless pump bottle, and is part of ...
(Date:9/16/2014)... UT (PRWEB) September 16, 2014 ... Solution, published new information on transitioning employees to ... Benefits, with the Affordable Care Act (ACA) in ... will be steering some or all of their ... no surprise. With guaranteed issue plans, coverage for ...
(Date:9/16/2014)... 17, 2014 UWDress.com, the well-known wedding ... elegant evening wear assortment online. Additionally, the firm ... people can access big discounts now, up to 62 ... evening gowns are charming; it has won a lot ... evening outfits, it is also providing big savings on ...
Breaking Medicine News(10 mins):Health News:Dog Food Secrets: Review Exposes Andrew Lewis’ Guide to Happier, Healthier Dogs with Homemade Dog Food 2Health News:A greater focus on socially disadvantaged women is needed to improve maternity care in England 2Health News:15% Off Face Whisperer® Neck & Decollete Cream Now from Sublime Beauty; Care For This Delicate Skin That Shows Age Quickly 2Health News:Zane Benefits Publishes New Information on Transitioning Employees to Individual Health Insurance 2Health News:New Elegant Evening Wear Assortment Released By UWDress.com 2
... as likely to miscarry during the first three weeks of ... study is the first of it’s kind to have established ... at an early stage. ,Cortisol is a hormone ... this hormone serve as a reliable stress indicator. Nearly 61 ...
... officially confirmed the cause of three dead swans found in Bulgaria ... It has said that it has confirmed it from the country's ... Lake in the Varna region and at Burgas beach have tested ... necessary steps by completely cordoning it off from the public. An ...
... is the second-biggest killer of women in UK. The recent reports ... they take a genetic breast cancer test caused a lot of ... 40,000 diagnoses are done each year and 13,000 deaths are expected. ... would not ask for women to take genetic breast cancer tests. ...
... spurt of fungal infections in contact lens wearers and this ... seven reported last month. //This takes the overall cases since ... infections and the Singapore National Eye Centre (SNEC) has treated ... and Lomb's (B&L) ReNu with MoistureLoc solution and the Health ...
... euthanasia campaigner Dr Philip Nitschke does not possess a license ... informs participants of their legal rights about ending their lives., ... registered as a doctor to carry out his euthanasia workshops. ... he needs a licence. He faces a criminal conviction if ...
... to a study by Emory University researcher Chensheng "Alex" ... two common pesticides used in U.S. agricultural production.'// ... of children with organic food items. The result was ... ,As stated by Dr. Lu, "The ...
Cached Medicine News:Health News:Early Miscarriage Common In Women Under Stress 2Health News:Health insurance in the future would depend on genetic test results 2
... original ultrasonic cement and ... an 11-year clinical history. ... array of tool tips ... applications, cemented and porous ...
... media meets today's ASHRAE challenges ... reduction. The unique, patented non-woven ... filters creates a media which ... to initial efficiency, average efficiency, ...
BRAT 2 Autologous Blood Recovery System gives performance, speed, versatility, and quality processing. , ,The BRAT 2 is now available with on-board Vacuum, programmability, plasma sequestration, Data...
The hipGRIP® is a twenty piece modular lateral positioning system which provides positive pelvis control with an innovative positioning system....
Medicine Products: